Volume 28, Number 7—July 2022
Research
Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
Merav Mofaz, Matan Yechezkel, Grace Guan, Margaret L. Brandeau, Tal Patalon, Sivan Gazit, Dan Yamin1, and Erez Shmueli1
Table
Characteristics of participants in study of self-reported and physiologic reactions to third BNT162b2 mRNA coronavirus disease (booster) vaccine dose*
| Characteristic | All participants, n = 1,609 | First dose, n = 223 | Second dose, n = 351 | Third dose, n = 1,344 |
|---|---|---|---|---|
| Sex | ||||
| M | 755 (46.92) | 101 (45.29) | 160 (45.58) | 639 (47.54) |
| F |
854 (53.08) |
122 (54.71) |
191 (54.42) |
705 (52.46) |
| Age group, y | ||||
| 18–29 | 226 (14.23) | 14 (6.28) | 39 (11.11) | 189 (14.06) |
| 30–39 | 272 (16.90) | 11 (4.93) | 53 (15.10) | 219 (16.29) |
| 40–49 | 177 (11.00) | 15 (6.73) | 42 (11.97) | 138 (10.27) |
| 50–59 | 420 (26.10) | 64 (28.70) | 87 (24.79) | 375 (27.90) |
| 60–69 | 358 (22.25) | 70 (31.39) | 75 (21.37) | 308 (22.92) |
| >70 |
153 (9.51) |
49 (21.97) |
55 (15.67) |
8.56 (115) |
| Body mass index, kg/m2 | ||||
| <30.0 | 1,258 (78.19) | 175 (78.48) | 280 (79.77) | 77.68 (1,044) |
| >30.0 | 330 (20.51) | 41 (18.39) | 60 (17.09) | 288 (21.43) |
| Unspecified |
21 (1.31) |
7 (3.14) |
11 (3.13) |
12 (0.89) |
| Underlying medical condition | ||||
| Hypertension | 228 (14.17) | 20.63 (46) | 15.95 (56) | 14.43 (194) |
| Diabetes | 139 (8.64) | 13.00 (29) | 7.98 (28) | 8.41 (113) |
| Heart disease | 77 (4.79) | 7.17 (16) | 4.56 (16) | 4.99 (67) |
| Chronic lung disease | 81 (5.03) | 4.93 (11) | 3.70 (13) | 5.21 (70) |
| Immune suppression | 13 (0.81) | 1.35 (3) | 0.85 (3) | 0.89 (12) |
| Cancer | 10 (0.62) | 0.45 (1) | 0.57 (2) | 0.67 (9) |
| Renal failure | 8 (0.50) | 1.79 (4) | 1.42 (5) | 0.45 (6) |
| None of the above | 1,180 (73.34) | 64.57 (144) | 72.08 (253) | 73.21 (984) |
| Unspecified | 17 (1.06) | 1.35 (3) | 2.85 (10) | 0.52 (7) |
*Values are no. (%). BNT162b2 vaccine, Pfizer-BioNTech (https://www.pfizer.com).
1These authors contributed equally to this article.
Page created: April 12, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.